Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Ping Li, Wei Liu, Shiguang Ye, Lili Zhou, Judy Zhu, Jiaqi Huang, Jing Li, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Xin Yao, Hui Wan, Yihong Yao, Aibin Liang, Dehui Zou

Blood (2023) 142 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2023-181527

Published: 2023

Journal Articles

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Kihyun Kim, Natalia Paola Schutz, Su-Peng Yeh, Estelle Verburgh, Fahad Alsharif, Wenming Chen, Tatiana Mitina, Wee-Joo Chng, Cathy Wu, Hui Wan, Zhongwen Huang, Meral Beksac

Blood (2021) 138 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2021-147108

Published: 2021

Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-134885

Published: 2020

Journal Articles

Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Su-Peng Yeh, MD, Fahad Alsharif, MD DIM, MB ChB, Meral Beksac, MD, Wenming Chen, PhD, Dorotea Fantl, MD, Tatiana Mitina, MD PhD, Estelle Verburgh, MBChB, M MDInt, FCPSA, PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Kwang-Wei Wu, MD, Zijing Zhang, PhD, Hui Wan, MD PhD, Kihyun Kim, MD

Blood (2019) 134 (Supplement_1): 5577.

https://doi.org/10.1182/blood-2019-122732

Published: 2019

Journal Articles

Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)

Burhan Ferhanoglu, MD, Tae Min Kim, Gayane Tumyan, DMSc, MD PhD, Su-Peng Yeh, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Amado Karduss, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, FAMS, Mubarak Al Mansour, MD, Silvia Rivas-Vera, MD, Yuqin Song, MD PhD, Marta Zerga, MD, Julie Blair, PhD MD MPhil, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg

Blood (2018) 132 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2018-99-111146

Published: 2018

Journal Articles

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Blood (2018) 132 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2018-99-116844

Published: 2018

NARROW

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Email alerts

ASH Publications

American Society of Hematology

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only